Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Hodgkin Disease 29Lymphoma 27HIV Infections 11Acquired Immunodeficiency Syndrome 10Testicular Neoplasms 9Teratoma 8Lymphoma, Non-Hodgkin 8Testicular Germ Cell Tumor 6Sarcoma, Kaposi 6Lymphoma, Follicular 6Endodermal Sinus Tumor 6Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, Large B-Cell, Diffuse 5Carcinoma, Embryonal 5Head and Neck Neoplasms 4Seminoma 3Neoplasm Metastasis 3Teratoma, Testicular 2Squamous Cell Carcinoma of Head and Neck 2Ovarian Germ Cell Cancer 2Neoplasms 2Drug-Related Side Effects and Adverse Reactions 2Cardiotoxicity 2Burkitt Lymphoma 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Skin Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Effusion, Malignant 1

Interventions

Brentuximab Vedotin 17fludarabine 9Cyclophosphamide 9dacetuzumab 6Lenalidomide 6Bortezomib 6ruxolitinib 5fludarabine phosphate 5Rituximab 5Melphalan 5Dexamethasone 4Busulfan 4lintuzumab 3Whole-Body Irradiation 3Mycophenolic Acid 3Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Doxorubicin 3Calcium Dobesilate 3Azacitidine 3vosaroxin 2spartalizumab 2ponatinib 2nilotinib 2Vincristine 2Thiotepa 2Tacrolimus 2Sugars 2Stem Cell Transplantation 2Rifampin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hematologic Diseases × Bleomycin × Clear all
NCT01060904 2014-12-18

A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma

Seagen Inc.

Phase 1 Completed
51 enrolled
Lymphoid

Hematologic Diseases, Hodgkin Disease, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡